Bristol-Myers: first quarter beats consensus

(CercleFinance.com) - The pharmaceutical laboratory Bristol-Myers Squibb announces Q1 2019 adjusted EPS that is up 17% at 1.
10 dollar, one cent more than analysts were expecting.

Its revenues rose 14% to 5.92 billion million over the period, backed by strong demand for Opdivo and Eliquis, as well as robust operational performance across the portfolio.

For FY 2019, Bristol-Myers Squibb has confirmed its target of adjusted EPS of between 4.10 dollars and 4.20 dollars. It also intends to finalise the acquisition of Celgene in the third quarter.

Copyright (c) 2019 CercleFinance.com. All rights reserved.